Part-Time
Mobile LVN/LPN
In-Home Services
IQVIA
10,001+ employees
Analytics, technology, and clinical research services.
Compensation Overview
$28/hr
Company Historically Provides H1B Sponsorship
Syracuse, NY, USA
In Person
Local travel within the designated geographic area is required, potentially up to 100 miles for patient visits.
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to IQVIA
See people who can refer or advise you
- An active and unrestricted Licensed Practical Nurse or Licensed Vocational Nurse license is required.
- Current cardiopulmonary resuscitation certification is required.
- A minimum of 2 years of phlebotomy experience in clinical or field settings is required.
- The ability to lift up to 70 pounds to transport medical or diagnostic equipment is required.
- The ability and willingness to travel up to 100 miles to conduct patient visits is required.
- Proficiency in using medical equipment and maintaining proper documentation practices is required.
- Strong interpersonal and communication skills with a patient-focused approach are required.
- Fluent spoken and written English is required.
- A valid driver's license is required, with a driving-record review before hire.
- Completion of a drug screening and background check after accepting an offer is required.
- Perform in-home blood specimen collection, labeling, and transportation according to network policies, procedures, and regulatory standards.
- Comply with laboratory safety and specimen-handling procedures and ensure appropriate delivery to designated laboratories.
- Conduct trained screenings, including electrocardiograms and macular edema screening examinations.
- Maintain a clean and organized work environment, including transportation and storage of supplies specific to the In-Home Network.
- Monitor and manage clinical supply inventory.
- Collaborate with the clinical coordination team to execute and submit visit-related paperwork promptly and accurately.
- Identify and report adverse events, medical product complaints, and patient inquiries according to company and manufacturer guidance.
- Maintain accurate mileage and time logs for reimbursement and compliance purposes.
- At least 1 year of electrocardiogram experience is preferred.
- Certification as a Certified Medical Assistant or Phlebotomy Technician is preferred.
IQVIA is a global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry. Its services combine deep clinical trial expertise with large datasets and analytics tools, delivered through the Connected Intelligence platform that links the healthcare ecosystem to generate insights while protecting patient privacy. The company differentiates itself by merging clinical research experience with expansive data resources and technology capabilities from its QuintilesIMS lineage, offering an integrated suite for faster research, development, and commercialization of medical treatments. IQVIA’s goal is to help pharmaceutical, biotech, and medical device companies, as well as researchers and governments, accelerate the development of new therapies and improve health outcomes.
Company Size
10,001+
Company Stage
IPO
Headquarters
Durham, North Carolina
Founded
1998
Get referred to IQVIA
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue rose 8.7% to $4.368 billion, beating estimates.
- R&D bookings surged 19% to $3.15 billion, lifting book-to-bill to 1.22.
- Medera and Kexing collaborations expand AI-enabled gene therapy and biosimilar demand.
What critics are saying
- CNIL fined IQVIA Operations France €5 million in May 2026 for health-data breaches.
- FTC blocked the DeepIntent acquisition in 2023, exposing future M&A friction.
- Morgan Stanley warned pharma could insource 30% of trial work, crushing IQVIA margins.
What makes IQVIA unique
- IQVIA.ai unifies clinical, commercial, and real-world workflows on one regulated platform.
- Nineteen of the top 20 pharma companies already use IQVIA AI workflows.
- $34.2 billion backlog locks in multiyear CRO and analytics revenue.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Life Insurance
Flexible Work Hours
Paid Vacation
Wellness Program
401(k) Retirement Plan
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -3%2 year growth
↓ -3%IQVIA and Medera to advance cardiac gene therapy and human-based drug discovery. August 04, 2026 16:15 ET | Source: Medera Inc. RESEARCH TRIANGLE PARK, N.C. and BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) - IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, and Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company pioneering next-generation therapeutics for cardiovascular disease, today announced a strategic collaboration to accelerate the development of cardiac gene therapies and human-based drug discovery platforms. The collaboration brings together IQVIA's global clinical trial and commercialization infrastructure with Medera's pioneering platforms: Sardocor, focused on developing disease-modifying gene therapies for difficult-to-treat cardiovascular diseases, and Novoheart, a leader in engineered human-based cardiac tissue for disease modelling and drug screening. Sardocor will leverage IQVIA's regulatory and trial execution expertise to advance its FDA-cleared, first-in-human AAV-based gene therapy programs. IQVIA will support patient recruitment, data quality and regulatory filings, including applications for expedited FDA designations. Novoheart's mini-Heart platform is already instrumental in securing IND and Fast Track designations and offers a predictive, human-based alternative to animal testing. The platform is expanding into multiple organ systems to support drug discovery and safety testing under the FDA Modernization Act 2.0. "By combining IQVIA's global expertise with Medera's mini-Heart platform and gene therapy programs, we can bring safer, more effective therapies to patients faster," said Ronald Li, Co-Founder, Chairman & CEO of Medera. "This collaboration expands our reach, while reinforcing the scientific and regulatory momentum around human-based drug discovery and cardiac gene therapy innovation." About IQVIA IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence(TM) to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI(R), advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 94,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide. IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. About Medera Inc. Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing next-generation therapeutics. Medera operates via two business units: Sardocor, its clinical development arm advancing a pipeline of cardiac gene therapy trials (HFpEF, HFrEF, DMD-CM), and Novoheart, its preclinical subsidiary pioneering the world's first and award-winning "mini-Heart" technology for human-based disease modelling, drug discovery, and toxicity testing. Novoheart's platforms have already supported FDA IND and Fast Track designations, and the company is advancing a broader pipeline of gene therapy, cell therapy, and small molecule candidates. For more information, visit www.medera.bio. | Contacts: | / | | Ally Stubin ICR Healthcare Media Relations 646-667-1861 [email protected] Stephanie Carrington ICR Healthcare Investor Relations 646-277-1282 [email protected] | Alissa Maupin IQVIA Media Relations 919-923-6785 [email protected] Kerri Joseph IQVIA Investor Relations 973-541-3558 [email protected] |
IQVIA Holdings Inc. (NYSE:IQV) receives consensus rating of "Moderate Buy" from brokerages. July 30, 2026 Key points. * Analysts maintain a bullish outlook: Sixteen brokerages assign IQVIA a consensus "Moderate Buy" rating, with 13 buys and three holds. The average 12-month price target is approximately $241.88, while several firms recently raised targets as high as $287. * Second-quarter performance exceeded expectations: Adjusted earnings were $3.15 per share versus the $3.03 consensus, while revenue increased 8.7% year over year to $4.37 billion. IQVIA also raised its fiscal 2026 earnings guidance to $12.80-$13.00 per share and cited record R&D bookings and a growing backlog. * Shares are near their 52-week high: IQVIA opened at $247.84, compared with a 52-week high of $251.36, and institutional investors own 89.62% of the stock. The company also has authorization for a $2 billion share repurchase program, covering up to 6.8% of outstanding shares. * Five stocks to consider instead of IQVIA. IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) has received an average rating of "Moderate Buy" from the sixteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $241.8824. Several analysts have commented on IQV shares. Mizuho increased their target price on IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a research note on Monday, July 13th. Barclays reaffirmed an "overweight" rating on shares of IQVIA in a report on Tuesday. Robert W. Baird lifted their price objective on IQVIA from $252.00 to $287.00 and gave the stock an "outperform" rating in a report on Wednesday. HSBC reissued a "buy" rating and issued a $240.00 target price on shares of IQVIA in a research report on Monday, July 6th. Finally, Stifel Nicolaus raised their price target on shares of IQVIA from $220.00 to $276.00 and gave the company a "buy" rating in a report on Wednesday. Key stories impacting IQVIA. Here are the key news stories impacting IQVIA this week: * Positive Sentiment: Second-quarter results exceeded expectations: IQVIA reported adjusted earnings of $3.15 per share versus the $3.03 consensus estimate, while revenue rose 8.7% year over year to $4.37 billion, above expectations of $4.30 billion. IQVIA Reports Second-Quarter 2026 Results * Positive Sentiment: Full-year guidance was raised: IQVIA now expects fiscal 2026 earnings of $12.80 to $13.00 per share, above the prior consensus estimate of $12.57. Revenue guidance of $17.3 billion to $17.5 billion also reflects continued expansion in the business. IQV Q2 Earnings Beat Estimates on R&D Bookings, Guidance Raised * Positive Sentiment: Demand indicators improved: Record R&D bookings, broad-based growth and a ballooning backlog suggest strong future revenue visibility and sustained demand for IQVIA's clinical-research and healthcare-intelligence services. IQVIA Stocks Rises on 2Q Gains, Ballooning Backlog * Positive Sentiment: Analysts became more bullish: JPMorgan raised its price target from $225 to $285 and assigned an "overweight" rating. Stifel lifted its target from $220 to $276 with a "buy" rating, while Robert W. Baird increased its target from $252 to $287 and maintained an "outperform" rating. These revisions indicate that analysts view the earnings beat and stronger outlook as durable catalysts. * Neutral Sentiment: IQVIA's new simplified organizational model is intended to improve collaboration and efficiency, but the financial benefits will depend on execution over time. The stock is also trading near its 52-week high, leaving less room for disappointment if growth or guidance momentum slows. Hedge funds weigh in on IQVIA. A number of institutional investors and hedge funds have recently modified their holdings of IQV. Vanguard Group Inc. increased its position in IQVIA by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 19,650,532 shares of the medical research company's stock valued at $4,429,426,000 after acquiring an additional 159,899 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of IQVIA by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 4,374,971 shares of the medical research company's stock valued at $982,272,000 after purchasing an additional 24,453 shares during the period. Boston Partners grew its stake in shares of IQVIA by 14.9% during the 4th quarter. Boston Partners now owns 4,087,380 shares of the medical research company's stock valued at $923,276,000 after purchasing an additional 530,672 shares during the period. JPMorgan Chase & Co. increased its position in shares of IQVIA by 16.2% during the 4th quarter. JPMorgan Chase & Co. now owns 3,799,600 shares of the medical research company's stock valued at $856,468,000 after purchasing an additional 528,753 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of IQVIA by 15.3% in the 3rd quarter. Invesco Ltd. now owns 2,773,984 shares of the medical research company's stock worth $526,891,000 after purchasing an additional 367,204 shares during the period. 89.62% of the stock is currently owned by hedge funds and other institutional investors. IQVIA stock up 2.0%. NYSE:IQV opened at $247.84 on Thursday. The firm has a market cap of $41.36 billion, a P/E ratio of 30.75, a P/E/G ratio of 2.18 and a beta of 1.20. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.75 and a current ratio of 0.71. IQVIA has a fifty-two week low of $154.50 and a fifty-two week high of $251.36. The firm has a 50-day simple moving average of $192.00 and a two-hundred day simple moving average of $186.89. IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts' consensus estimates of $3.03 by $0.12. The firm had revenue of $4.37 billion for the quarter, compared to analysts' expectations of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts predict that IQVIA will post 11.57 earnings per share for the current fiscal year. IQVIA announced that its Board of Directors has initiated a stock buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's management believes its stock is undervalued. About IQVIA. IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real-world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets. IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I-IV), real-world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider IQVIA, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list. While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.
IQVIA shares jumped 12.9% in morning trading after the clinical research company reported second-quarter results exceeding Wall Street expectations and raised its full-year guidance. The company posted revenue of $4.37 billion, up 8.7% year-on-year, beating estimates of $4.30 billion. Adjusted earnings per share reached $3.15, a 12.1% increase from the previous year, surpassing the consensus estimate of $3.03. Following the strong performance, IQVIA raised its full-year 2026 forecast. The company now projects revenue between $17.28 billion and $17.48 billion, with adjusted earnings per share ranging from $12.80 to $13.00. IQVIA shares are up 6.5% year-to-date and currently trade at $240.04, near their 52-week high of $244.29.
IQVIA reported second-quarter 2026 revenue of $4,368 million, up 8.7% year-over-year. The healthcare intelligence provider posted adjusted diluted earnings per share of $3.15, up 12.1%, and adjusted EBITDA of $994 million, up 9.2%. Commercial Solutions revenue reached $1,793 million, up 8.6%, whilst Research & Development Solutions revenue hit $2,575 million, up 8.8%. R&D Solutions generated record net new bookings of $3.15 billion, up 19%, with a 1.22x book-to-bill ratio. Operating cash flow rose 26% to $558 million. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and adjusted diluted earnings per share.
IQVIA Q2 earnings call highlights. July 28, 2026 Key points. * IQVIA exceeded Q2 expectations, with revenue up 8.7% to $4.368 billion, adjusted EBITDA rising 9.2% to $994 million and adjusted EPS increasing 12.1% to $3.15. * R&D Solutions bookings jumped 19.3% year over year to $3.15 billion, lifting the backlog to $34.2 billion. Commercial Solutions organic growth accelerated to 5%, supported by stronger product launches, customer demand and win rates. * IQVIA raised its 2026 outlook for revenue to $17.275 billion-$17.475 billion, adjusted EBITDA to $4.0 billion-$4.05 billion and adjusted EPS to $12.80-$13.00, while continuing investments in AI and productivity initiatives. * Five stocks we like better than IQVIA. IQVIA NYSE: IQV reported second-quarter results that exceeded the high end of its guidance, supported by accelerating organic revenue growth, higher R&D Solutions bookings and operational productivity gains. The company also raised its full-year outlook for revenue, adjusted EBITDA and adjusted diluted earnings per share. Chairman and Chief Executive Officer Ari Bousbib said revenue, adjusted EBITDA and adjusted diluted EPS all surpassed management's expectations. "The momentum we saw in the first quarter continued with improving market conditions and strong operational execution," Bousbib said. Second-quarter revenue totaled $4.368 billion, up 8.7% on a reported basis and 8.5% at constant currency. Acquisitions accounted for about 2.5 percentage points of the quarter's revenue growth, according to Executive Vice President and Chief Financial Officer Mike Fedock. Adjusted EBITDA rose 9.2% year over year to $994 million, while adjusted diluted EPS increased 12.1% to $3.15. On a GAAP basis, IQVIA reported net income of $256 million, or $1.53 per diluted share. R&D Solutions bookings and backlog increase. R&D Solutions revenue was $2.575 billion in the second quarter, rising 8.8% on a reported basis and 8.6% at constant currency. The business recorded $3.15 billion in net new bookings, up 19.3% from a year earlier and 27% sequentially, producing a book-to-bill ratio of 1.22. Fedock said cancellations remained within IQVIA's historical range. The company's R&D Solutions backlog stood at $34.2 billion as of June 30, with $9.23 billion expected to convert to revenue over the next 12 months, up 7.5% year over year. Last-12-month net new bookings reached $11.25 billion, an increase of 12.9% year over year. Bousbib said that metric has increased in each of the past four quarters and reflects both an improving demand environment and higher win rates. Management said bookings strength was broad-based rather than driven by unusually large contracts or changes in cancellation or pass-through trends. Bousbib said full-service outsourcing was strong, while functional service provider activity remained in the low- to mid-double-digit percentage range of total bookings. The company also updated its customer classifications for benchmarking purposes. Under the new definitions, IQVIA said large pharmaceutical companies account for about 50% of R&D Solutions revenue, midsize pharmaceutical companies account for about 15%, and emerging biopharma companies account for roughly 35%. Discover more Cryptocurrency News My MarketBeat Portfolio Financial Markets News Bousbib said emerging biopharma customers are a major source of industry innovation, noting that they account for about 70% of global clinical trial starts today, compared with about 45% a decade ago. He also said emerging biopharma research-and-development spending is expected to grow two to three times faster than large-pharma R&D spending. Commercial Solutions growth accelerates. Commercial Solutions revenue rose 8.6% on a reported basis and 8.4% at constant currency to $1.793 billion. Organic revenue growth in the segment accelerated to 5%, Bousbib said, as clients launched new products and broadened their use of IQVIA services. Analytics and consulting posted high-single-digit organic growth, its highest rate since 2022, according to management. Commercial engagement services and patient solutions continued to deliver double-digit year-over-year growth. Bousbib said the commercial environment has been supported by a nearly 45% increase in new drug launches during the first half of 2026 compared with the first half of 2025. He added that IQVIA's commercial pipeline has grown at a strong double-digit rate year to date, while customer decision timelines have shortened and win rates have increased. AI investments and productivity efforts. Management highlighted artificial intelligence as a differentiator in both clinical and commercial offerings. Bousbib said IQVIA has deployed 294 AI agents across 90 use cases and that 19 of the top 20 pharmaceutical companies have deployed IQVIA AI solutions in their workflows. Four of the top 10 pharmaceutical companies have contracted with IQVIA to co-develop AI solutions, he said. The company said its AI-enabled capabilities have contributed to clinical-trial awards by supporting site startup, enrollment, patient recruitment and patient-reported outcomes. In Commercial Solutions, IQVIA said clients are increasingly moving from AI pilots and data-foundation projects toward broader deployment of AI agents. Fedock said operational and productivity programs drove about 90 basis points of operational margin expansion during the second quarter. That improvement was partly offset by an approximately 80-basis-point margin drag from pass-through revenue growth, resulting in a 10-basis-point expansion in adjusted EBITDA margin. Second-quarter cash flow from operations was $558 million, while capital expenditures were $198 million, resulting in free cash flow of $360 million, up 23% year over year. IQVIA repurchased $398 million of shares during the quarter and $950 million during the first half, leaving approximately $2.8 billion under its existing repurchase authorization. Full-year outlook raised. IQVIA raised its 2026 revenue outlook to a range of $17.275 billion to $17.475 billion, representing reported growth of 5.9% to 7.1%. The new midpoint implies 6.5% growth, compared with the prior guidance midpoint of 5.8%. * Adjusted EBITDA is now expected to be $4 billion to $4.05 billion, up 5.6% to 6.9% year over year. * Adjusted EBITDA margin is expected to remain approximately flat year over year at about 23.2%. * Adjusted diluted EPS is forecast at $12.80 to $13.00, up 7.4% to 9.1% from 2025. * Third-quarter revenue is projected at $4.315 billion to $4.390 billion, with adjusted diluted EPS of $3.19 to $3.29. The company said its revised full-year outlook assumes about 200 basis points of contribution from acquisitions and approximately 20 basis points of foreign-exchange tailwind. IQVIA plans to hold an investor day on Dec. 2, 2026. About IQVIA (NYSE:IQV). IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real-world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets. IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I-IV), real-world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider IQVIA, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list. While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.